These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 35928283)

  • 41. DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease.
    de Souza MM; Cenci AR; Teixeira KF; Machado V; Mendes Schuler MCG; Gonçalves AE; Paula Dalmagro A; André Cazarin C; Gomes Ferreira LL; de Oliveira AS; Andricopulo AD
    Curr Med Chem; 2023; 30(6):669-688. PubMed ID: 35726411
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) enhances tau expression.
    Qian W; Jin N; Shi J; Yin X; Jin X; Wang S; Cao M; Iqbal K; Gong CX; Liu F
    J Alzheimers Dis; 2013; 37(3):529-38. PubMed ID: 23948904
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Altered regulation of tau phosphorylation in a mouse model of down syndrome aging.
    Sheppard O; Plattner F; Rubin A; Slender A; Linehan JM; Brandner S; Tybulewicz VL; Fisher EM; Wiseman FK
    Neurobiol Aging; 2012 Apr; 33(4):828.e31-44. PubMed ID: 21843906
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
    Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
    Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bidirectional Regulation of Amyloid Precursor Protein-Induced Memory Defects by Nebula/DSCR1: A Protein Upregulated in Alzheimer's Disease and Down Syndrome.
    Shaw JL; Zhang S; Chang KT
    J Neurosci; 2015 Aug; 35(32):11374-83. PubMed ID: 26269644
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Common genetic signatures of Alzheimer's disease in Down Syndrome.
    Sharma A; Chunduri A; Gopu A; Shatrowsky C; Crusio WE; Delprato A
    F1000Res; 2020; 9():1299. PubMed ID: 33633844
    [No Abstract]   [Full Text] [Related]  

  • 47. Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?
    Smith B; Medda F; Gokhale V; Dunckley T; Hulme C
    ACS Chem Neurosci; 2012 Nov; 3(11):857-72. PubMed ID: 23173067
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Abeta exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer's disease.
    Folwell J; Cowan CM; Ubhi KK; Shiabh H; Newman TA; Shepherd D; Mudher A
    Exp Neurol; 2010 Jun; 223(2):401-9. PubMed ID: 19782075
    [TBL] [Abstract][Full Text] [Related]  

  • 49. KAT7/HMGN1 signaling epigenetically induces tyrosine phosphorylation-regulated kinase 1A expression to ameliorate insulin resistance in Alzheimer's disease.
    Lu QS; Ma L; Jiang WJ; Wang XB; Lu M
    World J Psychiatry; 2024 Mar; 14(3):445-455. PubMed ID: 38617985
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dual-specificity tyrosine-phosphorylated and regulated kinase 1A (DYRK1A) interacts with the phytanoyl-CoA alpha-hydroxylase associated protein 1 (PAHX-AP1), a brain specific protein.
    Bescond M; Rahmani Z
    Int J Biochem Cell Biol; 2005 Apr; 37(4):775-83. PubMed ID: 15694837
    [TBL] [Abstract][Full Text] [Related]  

  • 51. DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients.
    Moreau M; Carmona-Iragui M; Altuna M; Dalzon L; Barroeta I; Vilaire M; Durand S; Fortea J; Rebillat AS; Janel N
    Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740400
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased dosage of DYRK1A leads to congenital heart defects in a mouse model of Down syndrome.
    Lana-Elola E; Aoidi R; Llorian M; Gibbins D; Buechsenschuetz C; Bussi C; Flynn H; Gilmore T; Watson-Scales S; Haugsten Hansen M; Hayward D; Song OR; Brault V; Herault Y; Deau E; Meijer L; Snijders AP; Gutierrez MG; Fisher EMC; Tybulewicz VLJ
    Sci Transl Med; 2024 Jan; 16(731):eadd6883. PubMed ID: 38266108
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of tau protein in neuronal damage in Alzheimer's disease and Down syndrome.
    Cárdenas AM; Ardiles AO; Barraza N; Baéz-Matus X; Caviedes P
    Arch Med Res; 2012 Nov; 43(8):645-54. PubMed ID: 23142525
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice.
    Yin X; Jin N; Shi J; Zhang Y; Wu Y; Gong CX; Iqbal K; Liu F
    Sci Rep; 2017 Apr; 7(1):619. PubMed ID: 28377597
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cell type- and brain structure-specific patterns of distribution of minibrain kinase in human brain.
    Wegiel J; Kuchna I; Nowicki K; Frackowiak J; Dowjat K; Silverman WP; Reisberg B; DeLeon M; Wisniewski T; Adayev T; Chen-Hwang MC; Hwang YW
    Brain Res; 2004 Jun; 1010(1-2):69-80. PubMed ID: 15126119
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice.
    Dewachter I; van Dorpe J; Spittaels K; Tesseur I; Van Den Haute C; Moechars D; Van Leuven F
    Exp Gerontol; 2000 Sep; 35(6-7):831-41. PubMed ID: 11053674
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cbs overdosage is necessary and sufficient to induce cognitive phenotypes in mouse models of Down syndrome and interacts genetically with Dyrk1a.
    Marechal D; Brault V; Leon A; Martin D; Lopes Pereira P; Loaëc N; Birling MC; Friocourt G; Blondel M; Herault Y
    Hum Mol Genet; 2019 May; 28(9):1561-1577. PubMed ID: 30649339
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies.
    Ferrer I; Gomez-Isla T; Puig B; Freixes M; Ribé E; Dalfó E; Avila J
    Curr Alzheimer Res; 2005 Jan; 2(1):3-18. PubMed ID: 15977985
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A three-dimensional human neural cell culture model of Alzheimer's disease.
    Choi SH; Kim YH; Hebisch M; Sliwinski C; Lee S; D'Avanzo C; Chen H; Hooli B; Asselin C; Muffat J; Klee JB; Zhang C; Wainger BJ; Peitz M; Kovacs DM; Woolf CJ; Wagner SL; Tanzi RE; Kim DY
    Nature; 2014 Nov; 515(7526):274-8. PubMed ID: 25307057
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Moderate Overexpression of Tau in Drosophila Exacerbates Amyloid-β-Induced Neuronal Phenotypes and Correlates with Tau Oligomerization.
    Miguel L; Frebourg T; Campion D; Lecourtois M
    J Alzheimers Dis; 2020; 74(2):637-647. PubMed ID: 32065789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.